Introduction

Methicillin-resistant Staphylococcus aureus (MRSA) induces sepsis, endocarditis, pneumonia and soft tissue infection and is difficult to treat because of the limited range of antibiotics to which MRSA is sensitive. Vancomycin is one of the effective antibiotics against MRSA, but vancomycin is associated with many adverse effects, including hypersensitivity reactions. There are two types of hypersensitivity reaction to vancomycin; an anaphylactoid reaction known as "red man syndrome" (RMS) and anaphylaxis (1). RMS involves non-immunological histamine release following rapid infusion of vancomycin and consists of pruritus, skin flushing in the upper chest, head and neck, and occasionally, hypotension. Lowering the vancomycin infusion rate relieves the symptoms and premedication with antihistamine is effective in preventing RMS. On the other hand, anaphylaxis is an immunologic reaction mediated by immunogloblin E (IgE) and is independent of the infusion rate. Readministration of vancomycin during anaphylaxis may cause respiratory arrest and thus desensitization is the only way to safely use vancomycin.
Several authors have reported desensitization protocols for vancomycin hypersensitivity (2) (3) (4) (5) (6) (7) (8) . The 
n s i t i z a t i o n , 5 0 ml o f Va n c o my c i n S o l u t i o n ( 5 0 0 mg i n 5 0 ml No r ma l S a l i n e ) wa s S e r i a l l y Di l u t e d T e n f o l d t o P r o d u c e F i v e 5 0 -ml S o l u t i o n s a t Co n c e n t r a t i o n s o f 1 : 1 0 , 1 : 1 0 0 , 1 : 1 , 0 0 0 , 1 : 1 0 , 0 0 0 a n d 1 : 1 0 0 , 0 0 0 . Va n c o my c i n wa s S l o wl y Admi n i s t e r e d , S t a r t i n g wi t h t h e Hi g h e s t Di l u t i o n a t a Ra t e o f 1 . 0 ml / mi n ( Va n c o my c i n I n f u s i o n Ra t e 0 . 0 0 0 1 mg / mi n ) f o r 1 0 mi n u t e s . Ne x t , a mo r e Co n c e n t r a t e d S o l u t i o n wa s Ad mi n i st e r e d a t a Ra t e o f 0 . 
Discussion
Hypersensitivity reactions to vancomycin include anaphylaxis and an anaphylactoid reaction known as RMS. According to the Gell and Cooms classification system, anaphylaxis is a type-I immune reaction that induces IgE-mediated release of histamine by mast cells and basophils (9, 10). The early phases of the anaphylactic reaction involve local edema, smooth muscle contraction, vasodilatation and increased permeability of postcapillary venules, while late reactions include urticaria, hypotension and brochospasms (4, 5). Anaphylaxis is independent of vancomycin infusion rate, but occurs within 1.5 hours of vancomycin exposure. In contrast, RMS involves IgE-independent histamine release from mast cells or basophils (11). Clinical symptoms of RMS include generalized flushing, pruiritus, erythematous rash, hypotension, dyspnea and chest pain (12). In addition, RMS is dependent on the vancomycin infusion rate (13). Tryptase, a component of mast cell granules, is elevated in the plasma of anaphylaxis patients, but not in the plasma of RMS patients (14, 15). However, it is sometimes difficult to distinguish between anaphylaxis and RMS.
In 
